Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines

Life Sciences
Vaibhav JadhavPurvi Bhatt

Abstract

Arsenic trioxide (As2O3) is a well-known anticancer drug and is approved by the FDA for its use in acute promyelocytic leukemia. In this study, anticancer and antiproliferative mechanism of biocompatible As2O3 nanoparticles was determined on human prostate cancer cell lines. In vitro anticancer efficacy of biopolymer coated As2O3 NPs was investigated in LNCaP and PC-3 cell lines, by assessing DNA damage, changes in epigenetic modulations, expression level of apoptotic markers and cell cycle analysis following treatment with As2O3 NPs. Our results demonstrate that the nanoparticulate formulation of dimercaptosuccinic acid (DMSA) and chitosan coated As2O3 is capable of inducing morphological changes, DNA damage and caspase-dependent apoptosis along with the expression of cyclin-dependent kinase inhibitor p21 by upregulation of Bax and downregulation of Bcl-2 and Bcl-xL proteins. The expression of cyclin-dependent kinase inhibitor - p21 was found to be triggered by changes in epigenetic modifications at histone tails. Biopolymer coated As2O3 nanoparticles induced reversal of mono, di and tri-methylation of histone H3 at lysine 9 residue. Acetylation of histone H3 at lysine 14 residue and phosphorylation of H3 at serine 10 residue ...Continue Reading

References

Aug 29, 1995·Proceedings of the National Academy of Sciences of the United States of America·M L AgarwalG R Stark
Aug 25, 1999·Histochemistry and Cell Biology·T GodardP Gauduchon
Aug 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Nov 27, 2002·European Journal of Clinical Pharmacology·C R KumanaY L Kwong
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·C A RothermundJ K Vishwanatha
Mar 22, 2003·Lancet·Angelo M DeMarzoJonathan I Epstein
Nov 9, 2005·Prostate Cancer and Prostatic Diseases·S R J BottM Williamson
Jan 4, 2006·Prostate Cancer and Prostatic Diseases·J H HongH Y Choi
Jan 6, 2007·Mutation Research·Omar GarciaTania Mandina
Apr 5, 2007·Nature Protocols·Peggy L Olive, Judit P Banáth
Nov 7, 2007·Prostate Cancer and Prostatic Diseases·J Miki, J S Rhim
May 15, 2010·Cell Death and Differentiation·J FüllgrabeB Joseph
Aug 11, 2010·Archives of Dermatological Research·S RamachandranS Karthikeyan
Aug 28, 2010·Journal of Hematology & Oncology·Clement YedjouRobert McMurray
Apr 20, 2011·Proceedings of the National Academy of Sciences of the United States of America·Lei ShiYongfeng Shang
May 21, 2011·Analytical Biochemistry·Gabriela Nestal de MoraesCinthya Sternberg
Aug 1, 2010·Therapeutic Delivery·Che-Ming Jack HuLiangfang Zhang
Sep 18, 2012·PloS One·Choon-Ho Park, Kyong-Tai Kim
Jan 26, 2013·PloS One·Luca BellucciKerstin Bystricky
May 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·Bridget T HughesBruce E Clurman
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Jul 2, 2015·Cancer Medicine·Kirsi M KaukoniemiTapio Visakorpi

❮ Previous
Next ❯

Citations

Feb 7, 2017·ACS Applied Materials & Interfaces·Paul A EllisonWeibo Cai
Feb 6, 2018·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Maneka HoonjanPurvi Bhatt
Jan 7, 2020·The International Journal of Occupational and Environmental Medicine·Rashid JahangirnejadMohsen Rezaei
Feb 10, 2017·Oncotarget·Adam P SageVictor D Martinez

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis